Topiramate: Safety in migraine patients
1★, 2, 3★ Corresponding author
- 1Department of Pharmacy Practice, Nandha College of Pharmacy, Erode, INDIA.
- 2Department of Pharmacy Practice, Drug and Poison Information Center, KMCH College of Pharmacy, Coimbatore, INDIA.
- 3Department of Neurology, Kovai Medical Center and Hospital, Coimbatore, INDIA.
CORRESPONDENCE
M. Ahamada Safna Mariyam
Department of Pharmacy Practice, Nandha College of Pharmacy, Erode, INDIA.
Volume 5, Issue 1 · pp. 30-31 · 2013 · DOI: 10.1016/j.jyp.2012.12.001
ABSTRACT
Topiramate, a sulfa-derivative monosaccharide was originally developed as a hypoglycemic agent, but was found to be devoid of hypoglycemic activity, and later, it was approved in 1995 in the UK as adjunctive treatment for partial-onset seizures.1 Topiramate with several mechanisms of actions, by its long half-life, high oral bioavailability, low protein binding, renal elimination, and with little or no hepatic metabolism, proves to be an ideal migraine prophylaxis medication, and was approved in 2004 by the Food and Drug Administration.2,3
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Mariyam, M. A. S., Sen, S., & Vijayan, K. (2013). Topiramate: Safety in migraine patients. Journal of Young Pharmacists, 5(1), 30-31. https://doi.org/10.1016/j.jyp.2012.12.001
Copyright and licence
© 2013 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0